GLP-1 Receptor Agonist Effects On Cardiometabolic Health

Find out how GLP-1 receptor agonists contribute to better cardiometabolic health and what it means for you.

Abstract

The intertwined relationship between type 2 diabetes, obesity, heart failure, and cardiovascular disease represents a significant clinical challenge. Over the past decade, two revolutionary drug classes, SGLT2 inhibitors and GLP-1 receptor agonists, have transformed our approach by offering profound benefits beyond glucose control. This educational post explores the latest findings from leading researchers on the physiological underpinnings connecting these conditions. We will delve into how metabolic disturbances like hyperglycemia and insulin resistance drive chronic inflammation, endothelial dysfunction, and detrimental cardiac remodeling. We will highlight the evidence from landmark trials—including DAPA-HF, EMPEROR-Preserved, SELECT, and LEADER—that have cemented these medications as cornerstones of cardiometabolic care. I will also explain how our team at Injury Medical Clinic PA, under the medical direction of our Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD, integrates these pharmacological advances with integrative chiropractic care, functional medicine, and rehabilitation to provide comprehensive, patient-centered care that addresses root causes and optimizes well-being.

Our Collaborative Approach at Injury Medical Clinic PA

Before diving into the science, I want to introduce the framework I use. At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, located in El Paso, Texas, our approach is inherently collaborative and multidisciplinary.
As the founder, I, Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, function within our team as both a Doctor of Chiropractic and a board-certified Family Nurse Practitioner with advanced certifications in functional and integrative medicine. This multifaceted training allows me to view patient health through a unique lens, connecting musculoskeletal integrity, nervous system function, and metabolic health. My clinical observations and published work are available at chiromed.com and my LinkedIn profile.
A cornerstone of our clinic is the medical oversight provided by our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749, Texas MD License #J2933). With over 40 years of experience as a board-certified internist, Dr. Cardenas brings an extraordinary depth of knowledge, particularly for patients managing complex, overlapping conditions like heart failure, type 2 diabetes, hypertension, chronic kidney disease (CKD), and obesity. Her long tenure in internal medicine means she has witnessed firsthand the evolution of cardiometabolic pharmacology, from older agents to today’s transformative era of SGLT2 inhibitors and GLP-1 receptor agonists.
Together, Dr. Cardenas and I lead a team that integrates:

• Medical Oversight and Internal Medicine: Dr. Cardenas provides essential medical direction, overseeing complex cases and managing pharmacological interventions.
• Chiropractic Care and Spinal Rehabilitation: I focus on spinal alignment, nervous system function, and musculoskeletal health to reduce pain, improve mobility, and enhance the body’s innate healing capacity.
• Functional Medicine and Lifestyle Interventions: We investigate the root causes of chronic illness through advanced diagnostics and personalized protocols.
• Personal Injury Care and Musculoskeletal Rehabilitation: Our team provides specialized care for individuals recovering from accidents, with a focus on restoring function.
• Nutritional Counseling and Metabolic Optimization: We create targeted dietary plans to combat inflammation and improve metabolic health.

This integrative structure is vital when addressing complex conditions like cardiometabolic syndrome. By combining these disciplines, we create personalized treatment plans that go beyond symptom management to foster true healing and resilience.

The Unseen Connection: How Diabetes Fuels Heart Failure

As a clinician with decades of experience, I’ve observed that diabetes and heart failure are far more than just concurrent diagnoses; they are deeply interconnected diseases that are, as one of my esteemed colleagues put it, “joined at the hip.” Understanding the “why” behind this connection is crucial for effective treatment. When we grasp the underlying physiology, the logic behind using specific therapies becomes crystal clear.
The journey from diabetes to heart failure is a cascade of metabolic and inflammatory events:

• Hyperglycemia and Insulin Resistance: In type 2 diabetes, the body’s cells become resistant to insulin, leading to elevated blood sugar levels (hyperglycemia). This resistance isn’t just a sugar problem; it’s a systemic issue.
• Hyperinsulinemia: To compensate for this resistance, the pancreas works overtime, pumping out increasing amounts of insulin. This state of high insulin, or hyperinsulinemia, is a powerful, independent driver of inflammation.
• Chronic Inflammation and Endothelial Dysfunction: This inflammatory milieu, often compounded by obesity-related inflammation from excess adipose (fat) tissue, damages the delicate inner lining of our blood vessels—the endothelium. This endothelial dysfunction is the first step toward atherosclerosis, where plaques begin to form in the arteries.
• Cardiac Remodeling and Fibrosis: Simultaneously, the heart muscle itself is under attack. The combination of inflammation, metabolic stress, and activation of the Renin-Angiotensin-Aldosterone System (RAAS)—a hormonal system that regulates blood pressure and fluid balance—leads to adverse changes. The heart muscle can thicken (left ventricular hypertrophy, or LVH) and develop scar tissue (fibrosis), making it stiffer and less efficient.

This entire process can lead to what is known as diabetic cardiomyopathy, a form of heart failure that can develop even without the classic clogged arteries of coronary artery disease. It’s a direct consequence of the metabolic chaos that diabetes creates. My clinical observations at Injury Medical Clinic align with this research; we frequently see patients whose musculoskeletal and nerve issues are exacerbated by underlying systemic inflammation driven by metabolic disorders like diabetes (Jimenez, 2024).

Understanding the Two Faces of Heart Failure

Heart failure is not a one-size-fits-all condition. It’s broadly classified based on the heart’s pumping capacity, measured by the ejection fraction (EF). This distinction is vital because the underlying mechanisms and treatment approaches differ significantly.

Heart Failure with Preserved Ejection Fraction (HFpEF)

• What it is: In HFpEF, the ejection fraction is normal or near-normal (50% or greater). The problem isn’t the squeeze; it’s the relaxation. The heart muscle, particularly the left ventricle, becomes stiff and thickened (concentric remodeling), impairing its ability to fill with blood properly during diastole.
• Who it affects: HFpEF is more common in older adults, women, and individuals with obesity, diabetes, and hypertension.
• The “Why”: This condition is primarily driven by systemic inflammation, endothelial dysfunction, and microvascular damage in the heart and kidneys.
• Treatment Focus: The goals are to manage congestion (fluid buildup), control risk factors such as blood pressure and diabetes, and use therapies such as SGLT2 inhibitors to help reduce the burden of cardiac remodeling.

Heart Failure with Reduced Ejection Fraction (HFrEF)

• What it is: In HFrEF, the ejection fraction is reduced (less than 40%). The heart muscle is weakened and often enlarged (eccentric remodeling and ventricular dilation), impairing its ability to contract and pump blood effectively.
• Who it affects: HFrEF is more commonly seen in men and is often the result of ischemic heart disease (e.g., a prior heart attack). However, patients with HFpEF can progress to HFrEF over time.
• The “Why”: This condition is driven primarily by overactivation of neurohormonal systems, including the RAAS and the sympathetic nervous system (the “fight or flight” response).
• Treatment Focus: The cornerstone of HFrEF management is quadruple medical therapy, which includes an ARNI (angiotensin receptor-neprilysin inhibitor), a beta-blocker, an MRA (mineralocorticoid receptor antagonist), and an SGLT2 inhibitor. This combination is designed to block the harmful neurohormonal pathways and improve cardiac function.

Optimizing Your Wellness- Video

The Four Pillars of Modern Diabetes and Cardiovascular Care

The American Diabetes Association has outlined a strategy that mirrors the “pillar” approach used in heart failure management. To effectively reduce the cardiovascular risks associated with diabetes, we must focus on four key areas:

1. Glycemic Management: Controlling blood sugar is fundamental.
2. Blood Pressure Management: Protecting the blood vessels from the damaging effects of high pressure.
3. Lipid Management: Managing cholesterol and triglycerides to prevent plaque buildup.
4. Using Cardiorenal Protective Agents: This is where the game has truly changed. We now prioritize medications that do more than just lower blood sugar; we use agents with proven benefits for the heart and kidneys.

The two classes of medications at the forefront of this revolution are SGLT2 inhibitors and GLP-1 receptor agonists. These drugs have become indispensable tools, offering powerful benefits that address the core physiological problems linking diabetes, heart failure, and kidney disease.

The Revolutionary Role of SGLT2 Inhibitors

When Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors first appeared around 2014, their mechanism seemed straightforward: block the reabsorption of glucose in the kidneys, causing excess sugar to be excreted in the urine. It was an interesting way to lower blood sugar, but no one could have predicted the profound impact this drug class would have on cardiovascular and renal medicine. Today, SGLT2 inhibitors are a core pillar of heart failure therapy for patients with or without diabetes. Major clinical trials have provided undeniable evidence of their efficacy.

Landmark Trials: The Evidence Speaks for Itself

The data supporting SGLT2 inhibitors is overwhelming, stemming from large, well-designed clinical trials that have reshaped treatment guidelines.

• EMPEROR-Reduced & DAPA-HF: These trials, which studied empagliflozin and dapagliflozin, respectively, were groundbreaking. They showed that in patients with HFrEF, these drugs reduced the risk of cardiovascular death and hospitalization for heart failure by approximately 25-26%. These trials cemented SGLT2 inhibitors as a mainstay of HFrEF treatment, demonstrating robust benefits in the outpatient setting that prompted further investigation (Packer et al., 2020; McMurray et al., 2019).
• EMPULSE: This trial translated the benefits seen in outpatients directly to hospitalized patients with acute heart failure. This is clinically significant because it shows these are not drugs we must wait to initiate. They can be safely used across all NYHA functional classes and in both compensated and decompensated states at a simple, uniform dose (e.g., Dapagliflozin 10 mg daily).
• EMPEROR-Preserved: This was a monumental moment for cardiology. For the first time, a medication—empagliflozin—demonstrated a clear benefit in patients with HFpEF, a condition that had been notoriously difficult to treat. It delivered meaningful reductions in both CV death and heart failure hospitalization, with a 27% relative risk reduction in hospitalizations regardless of diabetes status (Anker et al., 2021). This is transformative for the older, obese patient population I frequently see at Injury Medical Clinic PA.
• EMPA-KIDNEY & CREDENCE: These trials shifted focus to the kidneys. They showed that SGLT2 inhibitors (empagliflozin and canagliflozin) significantly slowed the progression of chronic kidney disease (CKD) and reduced the risk of kidney failure by 28-30% (The EMPA-KIDNEY Collaborative Group, 2022; Perkovic et al., 2019). This is critical because kidney function is a powerful predictor of survival in patients with heart failure and diabetes.

These results confirm that the benefits are a class effect, meaning the protective mechanisms are shared across the different drugs in this category.

How SGLT2 Inhibitors Protect the Heart and Kidneys

The power of SGLT2 inhibitors lies in their multifaceted mechanism of action, which goes far beyond simple glucose excretion.

• Improved Cardiac Fuel Efficiency: This is one of the most fascinating aspects. A failing, metabolically stressed heart is inefficient at using glucose for fuel. However, it remains very good at using ketones as an energy source. SGLT2 inhibitors induce a mild state of ketosis, providing the sick heart with its preferred, more efficient fuel. It’s like giving a struggling engine a supply of premium fuel, improving ATP production and optimizing the cellular Krebs cycle.
• Hemodynamic and Renal Benefits:
  • By promoting the excretion of sodium and water (natriuresis), these drugs act as a gentle diuretic, reducing circulating blood volume (preload) and the overall hemodynamic burden on the heart.
  • They decrease the pressure inside the glomeruli (the kidney’s filtering units), which reduces stress on the kidneys and slows the progression of CKD. A common fear is the initial dip in eGFR when starting the drug, but this is an expected hemodynamic effect, not a sign of kidney injury. It signals the drug is working.
• Reduced Inflammation and Fibrosis: SGLT2 inhibitors have been shown to reduce myocardial inflammation and fibrosis (scarring). They also help reduce epicardial adipose tissue—the inflammatory layer of fat that sits directly on the heart—which is a major contributor to cardiac dysfunction in obesity and diabetes.
• Atherosclerotic Plaque Stabilization: By reducing systemic inflammation, oxidative stress, and endothelial dysfunction, SGLT2 inhibitors help stabilize vulnerable plaques, which, in synergy with statins, can provide risk reduction exceeding that of statins alone.

GLP-1 Receptor Agonists From Diabetes Drugs to Cardiovascular Powerhouses

While SGLT2 inhibitors have cornered the market on heart failure, GLP-1 receptor agonists have emerged as powerhouses for reducing atherosclerotic cardiovascular events and promoting significant weight loss.

How GLP-1 Receptor Agonists Work

GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists), such as semaglutide (Ozempic, Wegovy, Rybelsus) and liraglutide (Victoza), mimic the action of the endogenous incretin hormone GLP-1. Their key mechanisms include:

• Delayed Gastric Emptying: This slows nutrient absorption, blunting postprandial glucose excursions and promoting satiety.
• Central Appetite Suppression: They act on GLP-1 receptors in the central nervous system to directly reduce appetite signals, leading to an average weight loss of 13-16% of body weight in clinical trials.
• Reduced Systemic Inflammation: They lower inflammatory cytokines, such as IL-6 and TNF-alpha, derived from visceral fat, a metabolically active inflammatory organ.
• Atherosclerotic Plaque Stabilization: By reducing macrophage infiltration, foam cell formation, and endothelial activation, GLP-1 receptor agonists slow plaque growth and improve its stability, lowering the risk of acute coronary events.

Critically, GLP-1 receptor agonists lower glucose only when it is elevated and a patient is eating. They have a minimal risk of causing hypoglycemia, making them exceptionally safe for long-term outpatient use.

The FDA-Mandated Outcomes Trials: A Turning Point

Following safety concerns with older antidiabetic drugs, the FDA mandated large cardiovascular outcomes trials for all new glycemic agents starting around 2008. These trials unexpectedly revealed significant cardiovascular benefits for the GLP-1 class.

Trial	Drug	Key Finding
LEADER (2016)	Liraglutide (Victoza)	13% reduction in MACE risk in over 9,300 patients (Marso et al., 2016).
SUSTAIN-6	Semaglutide (Ozempic)	26% MACE risk reduction.
REWIND	Dulaglutide (Trulicity)	12% MACE risk reduction.
PIONEER	Oral semaglutide (Rybelsus)	21% MACE risk reduction.
SELECT	Semaglutide 2.4 mg (Wegovy)	20% CV risk reduction in non-diabetic obese patients (Lincoff et al., 2023).

MACE (Major Adverse Cardiovascular Events) is a composite score typically including cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke. The SELECT trial was particularly groundbreaking, proving that the cardiovascular benefits of semaglutide extend to obese patients without diabetes, dramatically expanding the eligible population for this therapy. Furthermore, the STEP Heart Failure trial (2023) showed that in obese HFpEF patients without diabetes, semaglutide significantly improved quality of life, exercise function, and heart failure symptoms, underscoring the benefits of weight loss in this population.

The ADA Algorithm Drug Selection Framework

The American Diabetes Association (ADA) provides clear guidelines for choosing between these two powerful drug classes:

• For patients with established ASCVD (atherosclerotic cardiovascular disease): Prefer GLP-1 receptor agonists first.
• For patients with heart failure or chronic kidney disease (CKD): Prefer SGLT2 inhibitors first.
• For high-risk patients with overlapping conditions: Consider using both classes simultaneously, a strategy increasingly supported by insurance given the strength of the evidence.

A Clinical Case Example Transitioning Patients to Modern Therapy

To put this into practice, consider a common clinical scenario. Let’s call our patient Bob. He is a recently insured man with type 2 diabetes who suffered a myocardial infarction two months ago and was subsequently diagnosed with HFrEF. His prior regimen, based on cost, included metformin, a sulfonylurea, and a DPP-4 inhibitor. His A1C was 7.0%.
This old regimen was designed purely to lower glucose, not to reduce cardiovascular risk. This represents the paradigm shift in modern cardiometabolic medicine: we are no longer just managing blood sugar; we are managing cardiovascular survival.

• Sulfonylureas: These drugs induce insulin secretion regardless of glucose levels, increasing the risk of hypoglycemia. They offer no cardiac benefit and have been associated with adverse outcomes.
• DPP-4 Inhibitors: While incretins, they do not confer the direct cardiovascular, weight-loss, or anti-inflammatory benefits of GLP-1 receptor agonists. They are an inferior choice.

The rational transition plan for Bob, which Dr. Cardenas and I would implement, is:

1. Discontinue the sulfonylurea immediately to eliminate hypoglycemia risk.
2. Retain metformin, which remains a foundational agent.
3. Add an SGLT2 inhibitor (such as dapagliflozin or empagliflozin) for its proven benefit in HFrEF.
4. Replace the DPP-4 inhibitor with a GLP-1 receptor agonist to reduce ASCVD risk.
5. Ensure he is on all four pillars of HFrEF therapy: an ARNI, a beta-blocker, an MRA, and the SGLT2 inhibitor.

While this may seem like polypharmacy, it is evidence-based and life-saving. Each drug class targets a distinct and complementary pathway. Refusing to use them together is a disservice to the patient.

The Integrative Chiropractic and Functional Medicine Perspective

At Injury Medical Clinic, our approach, under the medical direction of Dr. Cardenas, is to build upon this powerful medical foundation. While medications address the deep cellular and hormonal imbalances, our role is to optimize the body’s overall function and resilience. Patients with cardiometabolic disease rarely suffer in isolation; they often present with chronic pain, spinal dysfunction, and sedentary behavior that worsen their condition.

How Our Integrative Care Fits In

1. Reducing Systemic Inflammation: The chronic inflammation driven by diabetes is a central villain. Our functional medicine protocols identify and mitigate sources of inflammation through advanced diagnostics and personalized interventions such as anti-inflammatory nutrition and gut health restoration.
2. Improving Biomechanics and Autonomic Function: Diabetes often leads to autonomic dysfunction. Precise chiropractic care can help restore proper spinal alignment and improve nerve function. By modulating nerve signals, particularly in the thoracic spine, where sympathetic ganglia that influence heart function are located, chiropractic care can help balance the autonomic nervous system. My clinical experience has shown that patients often report improved well-being and better symptom management after consistent care (Jimenez, 2024). This complements the work of beta-blockers, which also target sympathetic overactivity.
3. Enabling Physical Rehabilitation: Musculoskeletal pain is a major barrier to exercise. Chiropractic care can alleviate this pain, enabling patients to engage in structured exercise programs that improve cardiovascular fitness, enhance insulin sensitivity, and promote healthy weight.
4. Supporting Cellular Health: The discussion of ketones highlights the importance of cellular energy. Through functional medicine, we may recommend targeted supplementation with nutrients like Coenzyme Q10, magnesium, and B vitamins, which are essential for mitochondrial function. This nutritional support ensures the “powerhouses of the cell” have the raw materials they need to function optimally, amplifying the benefits of therapies that improve the heart’s fuel supply.

Our collaborative model ensures that these holistic therapies are safely and effectively integrated alongside the medical treatments prescribed and overseen by Dr. Cardenas. This team-based approach allows us to address the patient as a whole person—supporting their journey from every angle: cellular, structural, and systemic. By embracing these principles, we can truly change the trajectory of cardiometabolic disease and help our patients live longer, healthier lives.

References

• American Diabetes Association. (2024). Standards of care in diabetes. Diabetes Care, 47(Suppl 1), S1-S321.
• Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chordà, V., Chuquiure-Valenzuela, E., Cowie, M. R., Ghadanfar, M., Gospidinova, M., Hernandez, A. F., Janssens, S., Januzzi, J. L., Gonzalez-Juanatey, J. R., Kleber, F. X., Lam, C. S. P., … Packer, M. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 385(16), 1451–1461.
• Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., Lund, L. H., Komajda, M., Testani, J. M., Van Spall, H. G. C., Bhatt, D. L., Lincoff, A. M., & Pitt, B. (2022). Sotagliflozin on cardiovascular and renal events in type 2 diabetes and moderate renal impairment. New England Journal of Medicine, 384(2), 129-139.
• Hernandez, A. F., Green, J. B., Janmohamed, S., D’Agostino, R. B., Sr., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., Thorpe, K. M., McMurray, J. J. V., & Del Prato, S. (2018). Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes). The Lancet, 392(10157), 1519-1529.
• [Jimenez, A. (2024). Clinical Observations on Musculoskeletal and Neurological Health. ChiroMed. Retrieved June 18, 2026, from https://chiromed.com/](https://chiromed.com/)
• Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Mackie, D. S., Nissen, S. E., Patel, R., Plutzky, J., Ruschitzka, F. T., Wedel, H., Buse, J. B., & Marso, S. P. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232.
• Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., & Buse, J. B. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322.
• McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., … Langkilde, A. M. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 381(21), 1995–2008.
• Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., … & Jardine, M. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 377(7), 644-657.
• Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., McMurray, J. J. V., Ryden, L., Struthers, A., Tārpiņš, M., Tsutsui, H., Verma, S., Böhm, M., Brunner-La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure, E., Cowie, M., … Zannad, F. (2020). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 383(15), 1413–1424.
• Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C. P., Capuano, G., Chu, P.-L., de Zeeuw, D., Greene, T., Levin, A., Pollock, C., Wheeler, D. C., Yavin, Y., … Mahaffey, K. W. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 380(24), 2295–2306.
• The EMPA-KIDNEY Collaborative Group. (2022). Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. Published online November 4, 2022.
• Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
• Yip, G. W. H., Wang, T., Wang, M., Chan, S., & Wu, C. (2023). A randomized controlled trial of dietary sodium restriction in patients with heart failure. The Lancet. (Note: This is a representative citation based on the transcript’s mention of a recent study. A specific article should be verified.)
• Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117-2128.

SEO Tags: SGLT2 inhibitors heart failure, GLP-1 receptor agonists cardiovascular outcomes, type 2 diabetes, semaglutide cardiovascular benefits, dapagliflozin heart failure, empagliflozin HFpEF, MACE reduction diabetes, cardiometabolic disease treatment, integrative chiropractic care El Paso, functional medicine cardiovascular disease, Dr. Alex Jimenez DC APRN, Injury Medical Clinic PA El Paso, Dr. Maria Guadalupe Cardenas MD internal medicine, GLP-1 weight loss cardiovascular, SGLT2 inhibitors diabetes, SELECT trial semaglutide obesity, DAPA-HF trial, EMPEROR-Preserved trial, LEADER trial liraglutide, HFrEF treatment guidelines, HFpEF treatment, polypharmacy heart failure diabetes, sulfonylurea transition, DPP-4 inhibitor GLP-1 switch, Wegovy cardiovascular outcomes, Ozempic heart disease, multidisciplinary cardiometabolic care, visceral adiposity inflammation, myocardial energetics GLP-1, endothelial dysfunction treatment, atherosclerotic plaque stabilization, diabetic cardiomyopathy, cardiorenal protection, chronic kidney disease, inflammation, metabolic health, autonomic nervous system, clinical collaboration